1. Home
  2. REXR vs RGEN Comparison

REXR vs RGEN Comparison

Compare REXR & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REXR
  • RGEN
  • Stock Information
  • Founded
  • REXR 2013
  • RGEN 1981
  • Country
  • REXR United States
  • RGEN United States
  • Employees
  • REXR N/A
  • RGEN N/A
  • Industry
  • REXR Real Estate Investment Trusts
  • RGEN Medical/Dental Instruments
  • Sector
  • REXR Real Estate
  • RGEN Health Care
  • Exchange
  • REXR Nasdaq
  • RGEN Nasdaq
  • Market Cap
  • REXR 7.7B
  • RGEN 8.0B
  • IPO Year
  • REXR 2013
  • RGEN N/A
  • Fundamental
  • Price
  • REXR $34.67
  • RGEN $118.15
  • Analyst Decision
  • REXR Hold
  • RGEN Buy
  • Analyst Count
  • REXR 9
  • RGEN 12
  • Target Price
  • REXR $39.67
  • RGEN $172.67
  • AVG Volume (30 Days)
  • REXR 2.1M
  • RGEN 819.3K
  • Earning Date
  • REXR 07-16-2025
  • RGEN 04-29-2025
  • Dividend Yield
  • REXR 4.96%
  • RGEN N/A
  • EPS Growth
  • REXR 12.67
  • RGEN N/A
  • EPS
  • REXR 1.23
  • RGEN N/A
  • Revenue
  • REXR $974,598,000.00
  • RGEN $650,429,000.00
  • Revenue This Year
  • REXR $9.78
  • RGEN $13.93
  • Revenue Next Year
  • REXR $8.46
  • RGEN $14.35
  • P/E Ratio
  • REXR $28.20
  • RGEN N/A
  • Revenue Growth
  • REXR 18.04
  • RGEN 4.88
  • 52 Week Low
  • REXR $29.68
  • RGEN $102.97
  • 52 Week High
  • REXR $52.61
  • RGEN $182.52
  • Technical
  • Relative Strength Index (RSI)
  • REXR 49.50
  • RGEN 38.20
  • Support Level
  • REXR $33.82
  • RGEN $120.11
  • Resistance Level
  • REXR $35.77
  • RGEN $129.42
  • Average True Range (ATR)
  • REXR 0.73
  • RGEN 6.02
  • MACD
  • REXR 0.11
  • RGEN -1.20
  • Stochastic Oscillator
  • REXR 41.98
  • RGEN 5.96

About REXR Rexford Industrial Realty Inc.

Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: